{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "948e2a4e-b7dd-4fc1-96ec-258e5142d531",
   "metadata": {},
   "outputs": [],
   "source": [
    "# pip uninstall -y pyarrow\n",
    "# pip install --no-cache-dir pyarrow==17.0.0\n",
    "# pip install fastparquet"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "id": "5c75cbbd-1e6d-4386-bbd2-2f61fa89f5fc",
   "metadata": {},
   "outputs": [],
   "source": [
    "from datasets import load_dataset\n",
    "import google.generativeai as genai\n",
    "import json\n",
    "from langchain_google_genai import ChatGoogleGenerativeAI\n",
    "import random\n",
    "import os\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "id": "f1893318-1584-4945-a674-78032cf54a61",
   "metadata": {},
   "outputs": [],
   "source": [
    "if \"GOOGLE_API_KEY\" not in os.environ:\n",
    "    os.environ[\"GOOGLE_API_KEY\"] = \"<API_KEY>\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "id": "b205b994-7b6c-40f5-8bf6-97098f3447b2",
   "metadata": {},
   "outputs": [],
   "source": [
    "genai.configure(api_key=os.environ[\"GOOGLE_API_KEY\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "id": "ee1901eb-c9f1-4beb-a66e-e6df22f3f8bf",
   "metadata": {},
   "outputs": [],
   "source": [
    "ds = load_dataset(\"pubmed_qa\", \"pqa_labeled\")\n",
    "train_data = ds[\"train\"]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 64,
   "id": "3f883795-b843-4cd4-94f6-664bb5e9cadc",
   "metadata": {},
   "outputs": [],
   "source": [
    "def build_prompt(example, method=\"zero\", shots=[]):\n",
    "    if method == \"zero\":\n",
    "        return f\"\"\"You are a biomedical QA assistant.\n",
    "Answer the following question based only on the context provided.\n",
    "Provide a detailed descriptive answer with reasoning.\n",
    "\n",
    "Question: {example['question']}\n",
    "Context: {example['context']}\n",
    "Answer:\"\"\"\n",
    "    \n",
    "    elif method == \"one\":\n",
    "        demo = shots[0]\n",
    "        demo_prompt = f\"\"\"Example:\n",
    "Question: {demo['question']}\n",
    "Context: {demo['context']}\n",
    "Answer: {demo['final_decision']} (This is a concise label. \n",
    "Now provide detailed reasoning for new examples.)\"\"\"\n",
    "        \n",
    "        return demo_prompt + f\"\"\"\n",
    "\n",
    "Now answer this:\n",
    "Question: {example['question']}\n",
    "Context: {example['context']}\n",
    "Answer (detailed reasoning):\"\"\"\n",
    "    \n",
    "    elif method == \"few\":\n",
    "        demo_prompt = \"\\n\\n\".join(\n",
    "            [f\"Q: {s['question']}\\nContext: {s['context']}\\nAnswer: {s['final_decision']}\" for s in shots]\n",
    "        )\n",
    "        return demo_prompt + f\"\"\"\n",
    "\n",
    "Now answer this:\n",
    "Q: {example['question']}\n",
    "Context: {example['context']}\n",
    "Answer (detailed reasoning):\"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "id": "c7b3e3c1-48fe-4cd2-af7a-ca42a4edb77a",
   "metadata": {},
   "outputs": [],
   "source": [
    "def query_gemini(prompt, model=\"gemini-2.5-flash\"):\n",
    "    response = genai.GenerativeModel(model).generate_content(prompt)\n",
    "    return response.text.strip()\n",
    "\n",
    "samples = random.sample(list(train_data), 5)\n",
    "\n",
    "one_shot_example = random.choice(train_data)\n",
    "few_shot_examples = random.sample(list(train_data), 3)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 66,
   "id": "7c127483-69c2-4df8-b98c-70cc615de3d7",
   "metadata": {
    "collapsed": true,
    "jupyter": {
     "outputs_hidden": true
    },
    "scrolled": true
   },
   "outputs": [
    {
     "ename": "ResourceExhausted",
     "evalue": "429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits.\n* Quota exceeded for metric: generativelanguage.googleapis.com/generate_content_free_tier_requests, limit: 2\nPlease retry in 18.300096436s. [violations {\n  quota_metric: \"generativelanguage.googleapis.com/generate_content_free_tier_requests\"\n  quota_id: \"GenerateRequestsPerMinutePerProjectPerModel-FreeTier\"\n  quota_dimensions {\n    key: \"model\"\n    value: \"gemini-2.5-pro\"\n  }\n  quota_dimensions {\n    key: \"location\"\n    value: \"global\"\n  }\n  quota_value: 2\n}\n, links {\n  description: \"Learn more about Gemini API quotas\"\n  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n}\n, retry_delay {\n  seconds: 18\n}\n]",
     "output_type": "error",
     "traceback": [
      "\u001b[1;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[1;31mResourceExhausted\u001b[0m                         Traceback (most recent call last)",
      "Cell \u001b[1;32mIn[66], line 5\u001b[0m\n\u001b[0;32m      3\u001b[0m \u001b[38;5;28;01mfor\u001b[39;00m model \u001b[38;5;129;01min\u001b[39;00m [\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mgemini-2.5-flash\u001b[39m\u001b[38;5;124m\"\u001b[39m, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mgemini-2.5-pro\u001b[39m\u001b[38;5;124m\"\u001b[39m]:\n\u001b[0;32m      4\u001b[0m     \u001b[38;5;28;01mfor\u001b[39;00m s \u001b[38;5;129;01min\u001b[39;00m samples:\n\u001b[1;32m----> 5\u001b[0m         zero_ans \u001b[38;5;241m=\u001b[39m query_gemini(build_prompt(s, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mzero\u001b[39m\u001b[38;5;124m\"\u001b[39m), model)\n\u001b[0;32m      6\u001b[0m         one_ans \u001b[38;5;241m=\u001b[39m query_gemini(build_prompt(s, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mone\u001b[39m\u001b[38;5;124m\"\u001b[39m, [one_shot_example]), model)\n\u001b[0;32m      7\u001b[0m         few_ans \u001b[38;5;241m=\u001b[39m query_gemini(build_prompt(s, \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mfew\u001b[39m\u001b[38;5;124m\"\u001b[39m, few_shot_examples), model)\n",
      "Cell \u001b[1;32mIn[44], line 2\u001b[0m, in \u001b[0;36mquery_gemini\u001b[1;34m(prompt, model)\u001b[0m\n\u001b[0;32m      1\u001b[0m \u001b[38;5;28;01mdef\u001b[39;00m \u001b[38;5;21mquery_gemini\u001b[39m(prompt, model\u001b[38;5;241m=\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mgemini-2.5-flash\u001b[39m\u001b[38;5;124m\"\u001b[39m):\n\u001b[1;32m----> 2\u001b[0m     response \u001b[38;5;241m=\u001b[39m genai\u001b[38;5;241m.\u001b[39mGenerativeModel(model)\u001b[38;5;241m.\u001b[39mgenerate_content(prompt)\n\u001b[0;32m      3\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m response\u001b[38;5;241m.\u001b[39mtext\u001b[38;5;241m.\u001b[39mstrip()\n",
      "File \u001b[1;32m~\\anaconda3\\Lib\\site-packages\\google\\generativeai\\generative_models.py:331\u001b[0m, in \u001b[0;36mGenerativeModel.generate_content\u001b[1;34m(self, contents, generation_config, safety_settings, stream, tools, tool_config, request_options)\u001b[0m\n\u001b[0;32m    329\u001b[0m         \u001b[38;5;28;01mreturn\u001b[39;00m generation_types\u001b[38;5;241m.\u001b[39mGenerateContentResponse\u001b[38;5;241m.\u001b[39mfrom_iterator(iterator)\n\u001b[0;32m    330\u001b[0m     \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[1;32m--> 331\u001b[0m         response \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_client\u001b[38;5;241m.\u001b[39mgenerate_content(\n\u001b[0;32m    332\u001b[0m             request,\n\u001b[0;32m    333\u001b[0m             \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mrequest_options,\n\u001b[0;32m    334\u001b[0m         )\n\u001b[0;32m    335\u001b[0m         \u001b[38;5;28;01mreturn\u001b[39;00m generation_types\u001b[38;5;241m.\u001b[39mGenerateContentResponse\u001b[38;5;241m.\u001b[39mfrom_response(response)\n\u001b[0;32m    336\u001b[0m \u001b[38;5;28;01mexcept\u001b[39;00m google\u001b[38;5;241m.\u001b[39mapi_core\u001b[38;5;241m.\u001b[39mexceptions\u001b[38;5;241m.\u001b[39mInvalidArgument \u001b[38;5;28;01mas\u001b[39;00m e:\n",
      "File \u001b[1;32m~\\anaconda3\\Lib\\site-packages\\google\\ai\\generativelanguage_v1beta\\services\\generative_service\\client.py:835\u001b[0m, in \u001b[0;36mGenerativeServiceClient.generate_content\u001b[1;34m(self, request, model, contents, retry, timeout, metadata)\u001b[0m\n\u001b[0;32m    832\u001b[0m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_validate_universe_domain()\n\u001b[0;32m    834\u001b[0m \u001b[38;5;66;03m# Send the request.\u001b[39;00m\n\u001b[1;32m--> 835\u001b[0m response \u001b[38;5;241m=\u001b[39m rpc(\n\u001b[0;32m    836\u001b[0m     request,\n\u001b[0;32m    837\u001b[0m     retry\u001b[38;5;241m=\u001b[39mretry,\n\u001b[0;32m    838\u001b[0m     timeout\u001b[38;5;241m=\u001b[39mtimeout,\n\u001b[0;32m    839\u001b[0m     metadata\u001b[38;5;241m=\u001b[39mmetadata,\n\u001b[0;32m    840\u001b[0m )\n\u001b[0;32m    842\u001b[0m \u001b[38;5;66;03m# Done; return the response.\u001b[39;00m\n\u001b[0;32m    843\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m response\n",
      "File \u001b[1;32m~\\anaconda3\\Lib\\site-packages\\google\\api_core\\gapic_v1\\method.py:131\u001b[0m, in \u001b[0;36m_GapicCallable.__call__\u001b[1;34m(self, timeout, retry, compression, *args, **kwargs)\u001b[0m\n\u001b[0;32m    128\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_compression \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m:\n\u001b[0;32m    129\u001b[0m     kwargs[\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mcompression\u001b[39m\u001b[38;5;124m\"\u001b[39m] \u001b[38;5;241m=\u001b[39m compression\n\u001b[1;32m--> 131\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m wrapped_func(\u001b[38;5;241m*\u001b[39margs, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs)\n",
      "File \u001b[1;32m~\\anaconda3\\Lib\\site-packages\\google\\api_core\\retry\\retry_unary.py:293\u001b[0m, in \u001b[0;36mRetry.__call__.<locals>.retry_wrapped_func\u001b[1;34m(*args, **kwargs)\u001b[0m\n\u001b[0;32m    289\u001b[0m target \u001b[38;5;241m=\u001b[39m functools\u001b[38;5;241m.\u001b[39mpartial(func, \u001b[38;5;241m*\u001b[39margs, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs)\n\u001b[0;32m    290\u001b[0m sleep_generator \u001b[38;5;241m=\u001b[39m exponential_sleep_generator(\n\u001b[0;32m    291\u001b[0m     \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_initial, \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_maximum, multiplier\u001b[38;5;241m=\u001b[39m\u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_multiplier\n\u001b[0;32m    292\u001b[0m )\n\u001b[1;32m--> 293\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m retry_target(\n\u001b[0;32m    294\u001b[0m     target,\n\u001b[0;32m    295\u001b[0m     \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_predicate,\n\u001b[0;32m    296\u001b[0m     sleep_generator,\n\u001b[0;32m    297\u001b[0m     timeout\u001b[38;5;241m=\u001b[39m\u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_timeout,\n\u001b[0;32m    298\u001b[0m     on_error\u001b[38;5;241m=\u001b[39mon_error,\n\u001b[0;32m    299\u001b[0m )\n",
      "File \u001b[1;32m~\\anaconda3\\Lib\\site-packages\\google\\api_core\\retry\\retry_unary.py:153\u001b[0m, in \u001b[0;36mretry_target\u001b[1;34m(target, predicate, sleep_generator, timeout, on_error, exception_factory, **kwargs)\u001b[0m\n\u001b[0;32m    149\u001b[0m \u001b[38;5;66;03m# pylint: disable=broad-except\u001b[39;00m\n\u001b[0;32m    150\u001b[0m \u001b[38;5;66;03m# This function explicitly must deal with broad exceptions.\u001b[39;00m\n\u001b[0;32m    151\u001b[0m \u001b[38;5;28;01mexcept\u001b[39;00m \u001b[38;5;167;01mException\u001b[39;00m \u001b[38;5;28;01mas\u001b[39;00m exc:\n\u001b[0;32m    152\u001b[0m     \u001b[38;5;66;03m# defer to shared logic for handling errors\u001b[39;00m\n\u001b[1;32m--> 153\u001b[0m     _retry_error_helper(\n\u001b[0;32m    154\u001b[0m         exc,\n\u001b[0;32m    155\u001b[0m         deadline,\n\u001b[0;32m    156\u001b[0m         sleep,\n\u001b[0;32m    157\u001b[0m         error_list,\n\u001b[0;32m    158\u001b[0m         predicate,\n\u001b[0;32m    159\u001b[0m         on_error,\n\u001b[0;32m    160\u001b[0m         exception_factory,\n\u001b[0;32m    161\u001b[0m         timeout,\n\u001b[0;32m    162\u001b[0m     )\n\u001b[0;32m    163\u001b[0m     \u001b[38;5;66;03m# if exception not raised, sleep before next attempt\u001b[39;00m\n\u001b[0;32m    164\u001b[0m     time\u001b[38;5;241m.\u001b[39msleep(sleep)\n",
      "File \u001b[1;32m~\\anaconda3\\Lib\\site-packages\\google\\api_core\\retry\\retry_base.py:212\u001b[0m, in \u001b[0;36m_retry_error_helper\u001b[1;34m(exc, deadline, next_sleep, error_list, predicate_fn, on_error_fn, exc_factory_fn, original_timeout)\u001b[0m\n\u001b[0;32m    206\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m predicate_fn(exc):\n\u001b[0;32m    207\u001b[0m     final_exc, source_exc \u001b[38;5;241m=\u001b[39m exc_factory_fn(\n\u001b[0;32m    208\u001b[0m         error_list,\n\u001b[0;32m    209\u001b[0m         RetryFailureReason\u001b[38;5;241m.\u001b[39mNON_RETRYABLE_ERROR,\n\u001b[0;32m    210\u001b[0m         original_timeout,\n\u001b[0;32m    211\u001b[0m     )\n\u001b[1;32m--> 212\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m final_exc \u001b[38;5;28;01mfrom\u001b[39;00m \u001b[38;5;21;01msource_exc\u001b[39;00m\n\u001b[0;32m    213\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m on_error_fn \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m:\n\u001b[0;32m    214\u001b[0m     on_error_fn(exc)\n",
      "File \u001b[1;32m~\\anaconda3\\Lib\\site-packages\\google\\api_core\\retry\\retry_unary.py:144\u001b[0m, in \u001b[0;36mretry_target\u001b[1;34m(target, predicate, sleep_generator, timeout, on_error, exception_factory, **kwargs)\u001b[0m\n\u001b[0;32m    142\u001b[0m \u001b[38;5;28;01mfor\u001b[39;00m sleep \u001b[38;5;129;01min\u001b[39;00m sleep_generator:\n\u001b[0;32m    143\u001b[0m     \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[1;32m--> 144\u001b[0m         result \u001b[38;5;241m=\u001b[39m target()\n\u001b[0;32m    145\u001b[0m         \u001b[38;5;28;01mif\u001b[39;00m inspect\u001b[38;5;241m.\u001b[39misawaitable(result):\n\u001b[0;32m    146\u001b[0m             warnings\u001b[38;5;241m.\u001b[39mwarn(_ASYNC_RETRY_WARNING)\n",
      "File \u001b[1;32m~\\anaconda3\\Lib\\site-packages\\google\\api_core\\timeout.py:130\u001b[0m, in \u001b[0;36mTimeToDeadlineTimeout.__call__.<locals>.func_with_timeout\u001b[1;34m(*args, **kwargs)\u001b[0m\n\u001b[0;32m    126\u001b[0m         remaining_timeout \u001b[38;5;241m=\u001b[39m \u001b[38;5;28mself\u001b[39m\u001b[38;5;241m.\u001b[39m_timeout\n\u001b[0;32m    128\u001b[0m     kwargs[\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mtimeout\u001b[39m\u001b[38;5;124m\"\u001b[39m] \u001b[38;5;241m=\u001b[39m remaining_timeout\n\u001b[1;32m--> 130\u001b[0m \u001b[38;5;28;01mreturn\u001b[39;00m func(\u001b[38;5;241m*\u001b[39margs, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs)\n",
      "File \u001b[1;32m~\\anaconda3\\Lib\\site-packages\\google\\api_core\\grpc_helpers.py:78\u001b[0m, in \u001b[0;36m_wrap_unary_errors.<locals>.error_remapped_callable\u001b[1;34m(*args, **kwargs)\u001b[0m\n\u001b[0;32m     76\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m callable_(\u001b[38;5;241m*\u001b[39margs, \u001b[38;5;241m*\u001b[39m\u001b[38;5;241m*\u001b[39mkwargs)\n\u001b[0;32m     77\u001b[0m \u001b[38;5;28;01mexcept\u001b[39;00m grpc\u001b[38;5;241m.\u001b[39mRpcError \u001b[38;5;28;01mas\u001b[39;00m exc:\n\u001b[1;32m---> 78\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m exceptions\u001b[38;5;241m.\u001b[39mfrom_grpc_error(exc) \u001b[38;5;28;01mfrom\u001b[39;00m \u001b[38;5;21;01mexc\u001b[39;00m\n",
      "\u001b[1;31mResourceExhausted\u001b[0m: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits.\n* Quota exceeded for metric: generativelanguage.googleapis.com/generate_content_free_tier_requests, limit: 2\nPlease retry in 18.300096436s. [violations {\n  quota_metric: \"generativelanguage.googleapis.com/generate_content_free_tier_requests\"\n  quota_id: \"GenerateRequestsPerMinutePerProjectPerModel-FreeTier\"\n  quota_dimensions {\n    key: \"model\"\n    value: \"gemini-2.5-pro\"\n  }\n  quota_dimensions {\n    key: \"location\"\n    value: \"global\"\n  }\n  quota_value: 2\n}\n, links {\n  description: \"Learn more about Gemini API quotas\"\n  url: \"https://ai.google.dev/gemini-api/docs/rate-limits\"\n}\n, retry_delay {\n  seconds: 18\n}\n]"
     ]
    }
   ],
   "source": [
    "# Collect descriptive answers\n",
    "results = []\n",
    "for model in [\"gemini-2.5-flash\", \"gemini-2.5-pro\"]:\n",
    "    for s in samples:\n",
    "        zero_ans = query_gemini(build_prompt(s, \"zero\"), model)\n",
    "        one_ans = query_gemini(build_prompt(s, \"one\", [one_shot_example]), model)\n",
    "        few_ans = query_gemini(build_prompt(s, \"few\", few_shot_examples), model)\n",
    "\n",
    "        results.append({\n",
    "            \"model\": model,\n",
    "            \"question\": s[\"question\"],\n",
    "            \"context_snippet\": s[\"context\"],\n",
    "            \"gold_label\": s[\"final_decision\"],  # keep for reference\n",
    "            \"zero_shot_desc\": zero_ans,\n",
    "            \"one_shot_desc\": one_ans,\n",
    "            \"few_shot_desc\": few_ans\n",
    "        })"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 75,
   "id": "bb59659e-9436-4c03-85c4-5f3b07ee9743",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Show results\n",
    "import pandas as pd\n",
    "df = pd.DataFrame(results)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 73,
   "id": "b081a7b7-3ff2-435a-be7a-788730e793e9",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "========================================================================================================================\n",
      "Model: gemini-2.5-flash\n",
      "Question: The promise of specialty pharmaceuticals: are they worth the price?\n",
      "Context Snippet: {'contexts': ['Specialty pharmaceuticals have evolved beyond their status as niche drugs designed to treat rare conditions and are now poised to become the standard of care in a wide variety of common chronic illnesses. Due in part to the cost of these therapies, payers are increasingly demanding evidence of their value. Determining the value of these medications is hampered by a lack of robust pharmacoeconomic data.', 'To outline emerging strategies and case study examples for the medical and pharmacy benefits management of specialty pharmaceuticals.', 'The promise of specialty pharmaceuticals: increased life expectancy, improved quality of life, enhanced workplace productivity, decreased burden of disease, and reduced health care spending comes at a significant cost. These agents require special handling, administration, patient education, clinical support, and risk mitigation. Additionally, specialty drugs require distribution systems that ensure appropriate patient selection and data collection. With the specialty pharmaceutical pipeline overflowing with new medicines and an aging population increasingly relying on these novel treatments to treat common diseases, the challenge of managing the costs associated with these agents can be daunting. Aided by sophisticated pharmacoeconomic models to assess value, the cost impacts of these specialty drugs can be appropriately controlled.'], 'labels': ['BACKGROUND', 'OBJECTIVE', 'SUMMARY'], 'meshes': ['Chronic Disease', 'Drug Costs', 'Humans', 'Managed Care Programs', 'Pharmaceutical Preparations', 'Rare Diseases', 'United States'], 'reasoning_required_pred': ['m', 'a', 'y', 'b', 'e'], 'reasoning_free_pred': ['y', 'e', 's']}\n",
      "Gold Label: yes\n",
      "\n",
      "--- Zero-Shot Answer ---\n",
      "The promise of specialty pharmaceuticals is substantial, offering potential benefits such as increased life expectancy, improved quality of life, enhanced workplace productivity, decreased burden of disease, and even reduced health care spending.\n",
      "\n",
      "However, these benefits \"come at a significant cost.\" The high price of these therapies is a major concern, leading payers to increasingly demand evidence of their value. The complexity of these agents also adds to the cost and management burden, as they require special handling, administration, patient education, clinical support, risk mitigation, and specific distribution systems for appropriate patient selection and data collection.\n",
      "\n",
      "Determining the true value and whether they are \"worth the price\" is challenging due to a current \"lack of robust pharmacoeconomic data.\" The context highlights that the \"challenge of managing the costs associated with these agents can be daunting.\"\n",
      "\n",
      "Therefore, while the potential benefits are significant, the high cost, the operational complexities, and the current difficulty in definitively proving their value through robust data make their \"worth the price\" a complex question. The context suggests that with the aid of \"sophisticated pharmacoeconomic models to assess value,\" the cost impacts of these specialty drugs *can be appropriately controlled*, implying a path towards justifying their price and realizing their promise.\n",
      "\n",
      "--- One-Shot Answer ---\n",
      "The context indicates that specialty pharmaceuticals hold significant promise, including \"increased life expectancy, improved quality of life, enhanced workplace productivity, decreased burden of disease, and reduced health care spending.\" These benefits suggest they are indeed worth their price. However, the context also explicitly states that these benefits \"come at a significant cost\" and that determining their value is \"hampered by a lack of robust pharmacoeconomic data,\" requiring complex management and specialized distribution. Despite these challenges, the summary concludes that with \"sophisticated pharmacoeconomic models to assess value, the cost impacts of these specialty drugs can be appropriately controlled.\" Therefore, while their high cost and complexities are significant considerations, the potential for substantial patient and societal benefits, coupled with the ability to manage costs through value assessment, suggests they can be worth the price.\n",
      "\n",
      "--- Few-Shot Answer ---\n",
      "Answer (detailed reasoning): The context suggests that the worth of specialty pharmaceuticals for their price is a complex question without a simple \"yes\" or \"no\" answer. While the drugs offer a \"promise\" of significant benefits like increased life expectancy and improved quality of life, they also come \"at a significant cost\" and require special management. The text explicitly states that \"payers are increasingly demanding evidence of their value\" and that \"determining the value of these medications is hampered by a lack of robust pharmacoeconomic data.\" It further notes that \"sophisticated pharmacoeconomic models to assess value\" are needed to appropriately control their cost impacts. This indicates that their value-for-price is under assessment and not yet definitively established, hence \"maybe.\"\n",
      "========================================================================================================================\n",
      "\n",
      "\n",
      "========================================================================================================================\n",
      "Model: gemini-2.5-flash\n",
      "Question: Are sports medicine journals relevant and applicable to practitioners and athletes?\n",
      "Context Snippet: {'contexts': ['To examine the evidence base of sports medicine research and assess how relevant and applicable it is to everyday practice.', 'Original research articles, short reports, and case reports published in four major sport and exercise medicine journals were studied and classified according to the main topic of study and type of subjects used.', 'The most common topic was sports science, and very few studies related to the treatment of injuries and medical conditions. The majority of published articles used healthy subjects sampled from the sedentary population, and few studies have been carried out on injured participants.'], 'labels': ['OBJECTIVE', 'METHODS', 'RESULTS'], 'meshes': ['Health Personnel', 'Humans', 'Periodicals as Topic', 'Research', 'Sports', 'Sports Medicine'], 'reasoning_required_pred': ['n', 'o'], 'reasoning_free_pred': ['n', 'o']}\n",
      "Gold Label: no\n",
      "\n",
      "--- Zero-Shot Answer ---\n",
      "Based on the provided context, sports medicine journals appear to have limited direct relevance and applicability to practitioners and athletes, especially concerning the treatment of injuries and medical conditions.\n",
      "\n",
      "Here's the reasoning:\n",
      "*   **Topic Focus:** The study, which examined four major sport and exercise medicine journals, found that the most common topic was sports science. Crucially, \"very few studies related to the treatment of injuries and medical conditions.\" For practitioners who treat injuries and for athletes who experience them, this lack of focus on treatment makes the journals less directly applicable to their primary concerns.\n",
      "*   **Subject Population:** The majority of published articles used healthy subjects sampled from the sedentary population. In contrast, \"few studies have been carried out on injured participants.\" This means the research often doesn't reflect the populations practitioners treat (injured individuals) or the scenarios athletes face (managing injuries), thus limiting its direct practical application.\n",
      "\n",
      "Therefore, while these journals contribute to sports science, their content and the subjects studied suggest a gap in relevance for the immediate clinical practice of treating injuries and for athletes dealing with such conditions.\n",
      "\n",
      "--- One-Shot Answer ---\n",
      "No, according to the study, sports medicine journals are not highly relevant and applicable to practitioners and athletes. The research found that the most common topic in these journals was sports science, with \"very few studies related to the treatment of injuries and medical conditions.\" Additionally, the \"majority of published articles used healthy subjects sampled from the sedentary population,\" and \"few studies have been carried out on injured participants.\" These findings suggest a disconnect between the published research and the practical needs of practitioners and athletes, especially concerning injury treatment and conditions specific to injured populations.\n",
      "\n",
      "--- Few-Shot Answer ---\n",
      "No, the provided context suggests that sports medicine journals are *not* highly relevant and applicable to practitioners and athletes. The study found that \"very few studies related to the treatment of injuries and medical conditions\" and that \"the majority of published articles used healthy subjects sampled from the sedentary population, and few studies have been carried out on injured participants.\" This indicates a disconnect between the research published and the practical needs of practitioners and athletes, especially concerning injury management.\n",
      "========================================================================================================================\n",
      "\n",
      "\n",
      "========================================================================================================================\n",
      "Model: gemini-2.5-flash\n",
      "Question: Is there a relationship between rheumatoid arthritis and periodontal disease?\n",
      "Context Snippet: {'contexts': [\"1,412 individuals attending the University of Queensland's School of Dentistry were assessed for the prevalence of periodontal disease and rheumatoid arthritis. Analysis of data obtained from a self-reported health questionnaire and dental records was carried out and included: number of individuals referred for advanced periodontal care (test group); number of individuals attending for routine dentistry; determination of rheumatoid arthritis, cardiovascular disease and diabetes mellitus through self-reporting and assessment of prescription medications; assessment of periodontal disease through assessment of existing oral radiographs.\", 'In patients referred for periodontal treatment, the prevalence of self-reported rheumatoid arthritis was 3.95% which is significantly higher than that seen in patients not referred for periodontal treatment (0.66%) and also that reported in the general population (1%). Of those referred patients with rheumatoid arthritis, 62.5% had advanced forms of periodontal disease. These results were mirrored in the results of the self-reported prevalence of cardiovascular disease and diabetes mellitus which was consistent with the published higher prevalence in periodontal patients.'], 'labels': ['METHODS', 'RESULTS'], 'meshes': ['Adult', 'Aged', 'Alveolar Bone Loss', 'Arthritis, Rheumatoid', 'Cardiovascular Diseases', 'Dental Records', 'Diabetes Mellitus', 'Drug Prescriptions', 'Humans', 'Middle Aged', 'Periodontal Diseases', 'Periodontitis', 'Prevalence', 'Queensland', 'Radiography, Dental', 'Reproducibility of Results', 'Risk Factors', 'Surveys and Questionnaires'], 'reasoning_required_pred': ['y', 'e', 's'], 'reasoning_free_pred': ['y', 'e', 's']}\n",
      "Gold Label: yes\n",
      "\n",
      "--- Zero-Shot Answer ---\n",
      "Yes, the context provided indicates a relationship between rheumatoid arthritis and periodontal disease.\n",
      "\n",
      "**Reasoning:**\n",
      "\n",
      "1.  **Higher Prevalence of RA in Periodontal Patients:** The study found that the prevalence of self-reported rheumatoid arthritis (RA) was significantly higher in patients referred for advanced periodontal care (3.95%) compared to patients not referred for periodontal treatment (0.66%) and the general population (1%). This suggests an association where individuals with periodontal disease are more likely to also have rheumatoid arthritis.\n",
      "2.  **Advanced Periodontal Disease in RA Patients:** Among the patients referred for periodontal treatment who also reported having rheumatoid arthritis, a substantial majority (62.5%) had advanced forms of periodontal disease. This further strengthens the observed link, indicating that RA might be associated with more severe forms of periodontal disease.\n",
      "\n",
      "--- One-Shot Answer ---\n",
      "yes, there is a relationship between rheumatoid arthritis and periodontal disease. The study found that the prevalence of self-reported rheumatoid arthritis was significantly higher in patients referred for periodontal treatment (3.95%) compared to those not referred for periodontal treatment (0.66%) and the general population (1%). Furthermore, among those referred patients with rheumatoid arthritis, 62.5% had advanced forms of periodontal disease.\n",
      "\n",
      "--- Few-Shot Answer ---\n",
      "yes\n",
      "========================================================================================================================\n",
      "\n",
      "\n",
      "========================================================================================================================\n",
      "Model: gemini-2.5-flash\n",
      "Question: Percutaneous ethanol injection for benign cystic thyroid nodules: is aspiration of ethanol-mixed fluid advantageous?\n",
      "Context Snippet: {'contexts': ['We evaluated the differences between percutaneous ethanol injection with and without aspiration of ethanol-mixed fluid for treatment of benign cystic thyroid nodules.', 'We examined 60 patients with benign cystic thyroid nodules confirmed by fine-needle aspiration biopsy and divided them into 2 groups according to nonaspiration (group A, n = 30) or aspiration (group B, n = 30) of ethanol-mixed fluid after intracystic ethanol injection. We evaluated in both groups the complete disappearance of the cystic portion of the thyroid nodule on follow-up ultrasonography (first follow-up ultrasonography; mean, 4.6 months in group A; mean, 4.4 months in group B) (chi-square test), side effects or complications during and after the procedure (chi-square test), and the total procedure time (Student t test).', 'Most patients showed complete disappearance of the cystic portion of the thyroid nodule (group A, n = 29; group B, n = 28), and they revealed no recurrence on follow-up ultrasonography. There was no statistical difference in the success rates between group A and group B (P>.05). Pain, the most common side effect, and other mild side effects or complications occurred in small numbers of patients in each group, but there was no significant difference in side effects or complications between the 2 groups (P>.05), except for intracystic hemorrhage (P<.05) and the complaint of all group B patients due to a double puncture (P<.001). The total procedure time was nearly double in group B than in group A because of the additional procedures, such as complete evacuation of the ethanol-mixed fluid and the 10-minute compression.'], 'labels': ['BACKGROUND AND PURPOSE', 'METHODS', 'RESULTS'], 'meshes': ['Adult', 'Aged', 'Cysts', 'Ethanol', 'Female', 'Humans', 'Injections, Intralesional', 'Male', 'Middle Aged', 'Sclerotherapy', 'Suction', 'Thyroid Nodule', 'Treatment Outcome', 'Ultrasonography'], 'reasoning_required_pred': ['n', 'o'], 'reasoning_free_pred': ['n', 'o']}\n",
      "Gold Label: no\n",
      "\n",
      "--- Zero-Shot Answer ---\n",
      "No, based on the provided context, aspiration of ethanol-mixed fluid after percutaneous ethanol injection for benign cystic thyroid nodules does not appear to be advantageous. In fact, it presents several disadvantages.\n",
      "\n",
      "Here's the detailed reasoning:\n",
      "\n",
      "1.  **Success Rates:** The study found no statistical difference in the success rates between the non-aspiration group (Group A) and the aspiration group (Group B). In Group A (non-aspiration), 29 out of 30 patients showed complete disappearance of the cystic portion of the thyroid nodule, while in Group B (aspiration), 28 out of 30 patients showed the same. The P-value for this comparison was >.05, indicating no significant difference. Therefore, aspiration does not offer an advantage in terms of treatment efficacy.\n",
      "\n",
      "2.  **Side Effects and Complications:** While most side effects and complications, including pain (the most common side effect), were not significantly different between the two groups (P>.05), aspiration was associated with specific disadvantages:\n",
      "    *   **Intracystic Hemorrhage:** There was a statistically significant difference in intracystic hemorrhage, with the aspiration group (Group B) showing a higher occurrence (P<.05).\n",
      "    *   **Double Puncture Complaint:** All patients in the aspiration group (Group B) complained due to a double puncture (P<.001), indicating increased discomfort and procedural burden.\n",
      "    This suggests that aspiration can lead to certain complications and increased patient discomfort.\n",
      "\n",
      "3.  **Procedure Time:** The total procedure time was nearly double in the aspiration group (Group B) compared to the non-aspiration group (Group A). This increase in time was attributed to additional procedures required for aspiration, such as complete evacuation of the ethanol-mixed fluid and a 10-minute compression. A longer procedure time represents an operational disadvantage.\n",
      "\n",
      "In summary, aspiration of ethanol-mixed fluid does not improve the success rate, increases the procedure time, and is associated with a higher risk of intracystic hemorrhage and patient discomfort from a double puncture.\n",
      "\n",
      "--- One-Shot Answer ---\n",
      "No.\n",
      "The study compared percutaneous ethanol injection with and without aspiration of ethanol-mixed fluid for benign cystic thyroid nodules and found no advantage for aspiration.\n",
      "\n",
      "1.  **Efficacy:** There was no statistically significant difference in the complete disappearance rates of the cystic portion of the thyroid nodule between the aspiration group (group B) and the non-aspiration group (group A) (P>.05).\n",
      "2.  **Side Effects/Complications:** While most mild side effects showed no significant difference, the aspiration group had significantly more intracystic hemorrhage (P<.05) and all patients in this group complained about a double puncture (P<.001).\n",
      "3.  **Procedure Time:** The total procedure time was nearly double in the aspiration group compared to the non-aspiration group due to the additional steps involved.\n",
      "\n",
      "Therefore, aspiration of ethanol-mixed fluid offered no benefit in terms of success rate and presented disadvantages such as increased procedure time and specific complications/discomforts.\n",
      "\n",
      "--- Few-Shot Answer ---\n",
      "No.\n",
      "The study found no statistical difference in the success rates between percutaneous ethanol injection with and without aspiration of ethanol-mixed fluid for benign cystic thyroid nodules (P>.05). Furthermore, the aspiration group (group B) had a nearly double total procedure time and more complaints due to a double puncture, as well as a higher incidence of intracystic hemorrhage, indicating disadvantages rather than advantages.\n",
      "========================================================================================================================\n",
      "\n",
      "\n",
      "========================================================================================================================\n",
      "Model: gemini-2.5-flash\n",
      "Question: Does confined placental mosaicism account for adverse perinatal outcomes in IVF pregnancies?\n",
      "Context Snippet: {'contexts': ['IVF singletons have poorer perinatal outcomes than singletons from spontaneous conceptions. This may be due to the influence of ovarian stimulation on the chromosomal constitution of the embryos which could be translated into localized chromosomal anomalies in the placenta. The aim of this study was to compare the incidence of confined placental mosaicism (CPM) in IVF/ICSI pregnancies and spontaneous conceptions.', 'We conducted a multi-centre retrospective analysis of karyotype results obtained by chorionic villus sampling (CVS), performed due to advanced maternal age (>or=36 years at 18 weeks of gestation), in the Netherlands between 1995 and 2005.', 'From a total of 322 246 pregnancies, 20 885 CVS results were analysed: 235 in the IVF/ICSI group and 20 650 in the control group. The mean age of women in both groups was 38.4 years (mean difference -0.08, 95% CI -0.35 to 0.18). Data relating to the fetal karyotype were missing in 143 cases in the control group. When taking into account missing data, the incidence of CPM was lower in the IVF-ICSI group than in the control group, 1.3% versus 2.2% (odds ratio 0.59, 95% CI 0.19-1.85), whereas the incidence of fetal chromosomal anomalies was increased 4.3% versus 2.4% (odds ratio 1.81, 95% CI 0.95-3.42). Neither differences were statistically significant.'], 'labels': ['BACKGROUND', 'METHODS', 'RESULTS'], 'meshes': ['Adult', 'Chorionic Villi Sampling', 'Female', 'Fertilization in Vitro', 'Fetus', 'Humans', 'Karyotyping', 'Mosaicism', 'Ovulation Induction', 'Placenta', 'Pregnancy', 'Pregnancy Outcome', 'Retrospective Studies', 'Sperm Injections, Intracytoplasmic'], 'reasoning_required_pred': ['n', 'o'], 'reasoning_free_pred': ['n', 'o']}\n",
      "Gold Label: no\n",
      "\n",
      "--- Zero-Shot Answer ---\n",
      "Based on the context provided, there is no evidence to suggest that confined placental mosaicism (CPM) accounts for adverse perinatal outcomes in IVF pregnancies. In fact, the findings presented contradict this idea.\n",
      "\n",
      "Here's the reasoning:\n",
      "1.  **Acknowledged Poorer Outcomes:** The context states that \"IVF singletons have poorer perinatal outcomes than singletons from spontaneous conceptions.\"\n",
      "2.  **Initial Hypothesis:** The study's background section initially hypothesized that these poorer outcomes \"may be due to the influence of ovarian stimulation on the chromosomal constitution of the embryos which could be translated into localized chromosomal anomalies in the placenta.\" This suggests CPM as a potential factor.\n",
      "3.  **Study's Findings on CPM Incidence:** However, the results of the study show that \"the incidence of CPM was lower in the IVF-ICSI group than in the control group, 1.3% versus 2.2%.\"\n",
      "4.  **Contradictory Evidence:** If IVF pregnancies have poorer perinatal outcomes but a *lower* incidence of CPM, then CPM cannot logically account for or explain these adverse outcomes. A lower incidence of CPM in the IVF group directly refutes the idea that CPM is a contributing factor to their observed poorer perinatal outcomes.\n",
      "5.  **Study's Scope:** The study's aim was to compare the incidence of CPM, not to establish a causal link between CPM and adverse perinatal outcomes themselves.\n",
      "\n",
      "--- One-Shot Answer ---\n",
      "No.\n",
      "The study investigated whether confined placental mosaicism (CPM) could account for poorer perinatal outcomes in IVF pregnancies. However, the results showed that the incidence of CPM was *lower* in the IVF/ICSI group (1.3%) compared to the control group of spontaneous conceptions (2.2%). Furthermore, this difference was not statistically significant. Therefore, based on these findings, confined placental mosaicism does not appear to account for adverse perinatal outcomes in IVF pregnancies.\n",
      "\n",
      "--- Few-Shot Answer ---\n",
      "The study investigated whether confined placental mosaicism (CPM) was related to the poorer perinatal outcomes observed in IVF singletons. The results indicated that the incidence of CPM was lower in the IVF-ICSI group (1.3%) compared to the control group (2.2%). Importantly, this difference was not statistically significant.\n",
      "\n",
      "Therefore, the study's findings do not support the idea that confined placental mosaicism accounts for adverse perinatal outcomes in IVF pregnancies; in fact, the incidence was found to be numerically lower in IVF pregnancies, though not statistically significant.\n",
      "========================================================================================================================\n",
      "\n",
      "\n",
      "========================================================================================================================\n",
      "Model: gemini-2.5-pro\n",
      "Question: The promise of specialty pharmaceuticals: are they worth the price?\n",
      "Context Snippet: {'contexts': ['Specialty pharmaceuticals have evolved beyond their status as niche drugs designed to treat rare conditions and are now poised to become the standard of care in a wide variety of common chronic illnesses. Due in part to the cost of these therapies, payers are increasingly demanding evidence of their value. Determining the value of these medications is hampered by a lack of robust pharmacoeconomic data.', 'To outline emerging strategies and case study examples for the medical and pharmacy benefits management of specialty pharmaceuticals.', 'The promise of specialty pharmaceuticals: increased life expectancy, improved quality of life, enhanced workplace productivity, decreased burden of disease, and reduced health care spending comes at a significant cost. These agents require special handling, administration, patient education, clinical support, and risk mitigation. Additionally, specialty drugs require distribution systems that ensure appropriate patient selection and data collection. With the specialty pharmaceutical pipeline overflowing with new medicines and an aging population increasingly relying on these novel treatments to treat common diseases, the challenge of managing the costs associated with these agents can be daunting. Aided by sophisticated pharmacoeconomic models to assess value, the cost impacts of these specialty drugs can be appropriately controlled.'], 'labels': ['BACKGROUND', 'OBJECTIVE', 'SUMMARY'], 'meshes': ['Chronic Disease', 'Drug Costs', 'Humans', 'Managed Care Programs', 'Pharmaceutical Preparations', 'Rare Diseases', 'United States'], 'reasoning_required_pred': ['m', 'a', 'y', 'b', 'e'], 'reasoning_free_pred': ['y', 'e', 's']}\n",
      "Gold Label: yes\n",
      "\n",
      "--- Zero-Shot Answer ---\n",
      "Based on the context provided, the question of whether specialty pharmaceuticals are worth their price is presented as a complex issue with significant arguments on both sides. The context does not give a simple yes or no answer, but instead outlines the balance between their promise and their cost.\n",
      "\n",
      "**The Promise (Why they may be worth the price):**\n",
      "\n",
      "The context explicitly states that the \"promise of specialty pharmaceuticals\" is substantial. The potential benefits that contribute to their value include:\n",
      "*   **Increased life expectancy and improved quality of life:** These drugs are designed to treat what are often rare or chronic and debilitating illnesses.\n",
      "*   **Enhanced workplace productivity and decreased burden of disease:** By effectively treating these conditions, patients can lead more productive lives.\n",
      "*   **Reduced overall health care spending:** While the drugs themselves are expensive, they may offset other costs by preventing hospitalizations, reducing the need for other treatments, and lowering the overall burden on the healthcare system.\n",
      "\n",
      "**The Cost (The challenge to their worth):**\n",
      "\n",
      "The text makes it clear that these benefits come at a \"significant cost.\" The price is not limited to the medication alone but also includes a range of associated expenses:\n",
      "*   **Special Requirements:** These agents require special handling, administration, patient education, and clinical support.\n",
      "*   **Risk Mitigation and Distribution:** They necessitate complex distribution systems to ensure appropriate patient selection and data collection, adding to the overall cost.\n",
      "*   **High Demand:** An \"aging population increasingly relying on these novel treatments\" and an \"overflowing\" pipeline of new medicines create a \"daunting\" challenge for managing the associated costs.\n",
      "\n",
      "**The Determination of Value:**\n",
      "\n",
      "The core of the issue, according to the context, is the difficulty in formally determining their value. Payers are \"increasingly demanding evidence of their value,\" but this process is \"hampered by a lack of robust pharmacoeconomic data.\" However, the text suggests a path forward. It states that \"Aided by sophisticated pharmacoeconomic models to assess value, the cost impacts of these specialty drugs can be appropriately controlled.\"\n",
      "\n",
      "**Conclusion:**\n",
      "\n",
      "In summary, the context suggests that specialty pharmaceuticals are not inherently \"worth the price\" or \"not worth the price.\" Instead, their value is conditional and must be carefully assessed. They offer a significant promise to improve and extend lives, but their high and multifaceted costs pose a major challenge. The ultimate worth of these drugs can only be determined through the use of sophisticated pharmacoeconomic models that can properly weigh their substantial benefits against their significant costs.\n",
      "\n",
      "--- One-Shot Answer ---\n",
      "maybe (The provided text presents a balanced view, highlighting both the significant benefits and the substantial costs and challenges associated with specialty pharmaceuticals, without reaching a definitive conclusion on their worth.)\n",
      "The text does not provide a simple \"yes\" or \"no\" answer. It frames the question as a central challenge in healthcare.\n",
      "*   **Arguments for \"Yes, they are worth it\":** The summary lists substantial promises, including \"increased life expectancy, improved quality of life, enhanced workplace productivity, decreased burden of disease, and reduced health care spending.\"\n",
      "*   **Arguments for \"No, they are not worth it\" (or \"It's complicated\"):** These benefits come at a \"significant cost.\" The text also notes that \"Determining the value of these medications is hampered by a lack of robust pharmacoeconomic data.\"\n",
      "*   **Conclusion:** The text suggests that the value of these drugs is conditional. It concludes that with the help of \"sophisticated pharmacoeconomic models,\" their costs \"can be appropriately controlled,\" implying that their worth needs to be actively managed and assessed, rather than being inherently guaranteed. Therefore, the answer is \"maybe.\"\n",
      "\n",
      "--- Few-Shot Answer ---\n",
      "The provided text does not definitively state whether specialty pharmaceuticals are worth their price. It presents both the potential benefits and the significant costs, framing it as an ongoing challenge. The text mentions that \"payers are increasingly demanding evidence of their value\" and that \"determining the value of these medications is hampered by a lack of robust pharmacoeconomic data.\" While it outlines the \"promise\" of these drugs, such as \"increased life expectancy\" and \"improved quality of life,\" it immediately notes this \"comes at a significant cost.\" The summary suggests that with the right models, costs can be \"appropriately controlled,\" but it doesn't conclude that their value has been proven to justify the price across the board. Therefore, the answer is conditional.\n",
      "Answer: maybe\n",
      "========================================================================================================================\n",
      "\n"
     ]
    }
   ],
   "source": [
    "# Function to display long text neatly\n",
    "def print_descriptive_results(df, width=100):\n",
    "    for idx, row in df.iterrows():\n",
    "        print(f\"\\n{'='*120}\")\n",
    "        print(f\"Model: {row['model']}\")\n",
    "        print(f\"Question: {row['question']}\")\n",
    "        print(f\"Context Snippet: {row['context_snippet']}\")\n",
    "        print(f\"Gold Label: {row['gold_label']}\")\n",
    "        print(f\"\\n--- Zero-Shot Answer ---\\n{row['zero_shot_desc']}\")\n",
    "        print(f\"\\n--- One-Shot Answer ---\\n{row['one_shot_desc']}\")\n",
    "        print(f\"\\n--- Few-Shot Answer ---\\n{row['few_shot_desc']}\")\n",
    "        print(f\"{'='*120}\\n\")\n",
    "\n",
    "# Display results\n",
    "print_descriptive_results(df)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "253a9805-9ed4-4bc8-8f58-ac0b68a161f0",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python [conda env:base] *",
   "language": "python",
   "name": "conda-base-py"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.7"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
